Non-ST Elevation Myocardial Infarction Clinical Trial
Official title:
Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
Some patients have a poor response to dual antiplatelet therapy (DAPT), and it can result in
a poor prognosis after percutaneous coronary intervention (PCI). Devices like Ultegra Rapid
Platelet Function Analyzer (VerifyNow®) enable us to quantify platelet reactivity quickly in
the catheter laboratory. This means that the poor responders to DAPT can be identified, and
the patients' outcomes can be improved by providing additional antiplatelet agents.
Tirofiban, a GP IIb/IIIa inhibitor, is a potent antiplatelet agent which is recommended for
Non-ST-Elevation acute coronary syndrome (NSTE-ACS) with high risk at presentation. However,
its role is not clear for patients stabilized with standard medical treatment but with a poor
responsiveness to DAPT.
In this study, Investigators administered tirofiban on top of DAPT to patients with NSTE-ACS
undergoing PCI who have a high platelet reactivity (HPR) identified by VerifyNow.
To the best of our knowledge, there are few studies conducted with tirofiban for tailored
antiplatelet therapy. Moreover, this is the first randomized study with NSTE-ACS patients for
tailored use of tirofiban under the guidance of platelet reactivity.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03278509 -
Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
|
Phase 4 | |
Active, not recruiting |
NCT03646357 -
BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function
|
Phase 4 | |
Recruiting |
NCT05230446 -
PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions
|
N/A | |
Completed |
NCT02983123 -
One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome
|
||
Recruiting |
NCT03541109 -
A Polypill for Secondary Prevention of Ischemic Heart Disease
|
Phase 3 | |
Completed |
NCT03395041 -
Periodontal Disease, Inflammation and Acute Coronary Syndromes
|
||
Recruiting |
NCT03863327 -
EKG Criteria and Identification of Acute Coronary Occlusion
|
||
Completed |
NCT03389503 -
Comparison of Left and Right Transradial Approach for CAG and PCI
|
N/A | |
Completed |
NCT03208153 -
the Invasive and Conservative Strategies in Elderly Frail Patients With Non-STEMI
|
N/A | |
Completed |
NCT03690713 -
International Collaboration of Comprehensive Physiologic Assessment
|
||
Completed |
NCT04161378 -
Impact of Cardiac Rehabilitation Programs on Left Ventricular Remodeling After Acute Myocardial Infarction - the REHAB Trial
|
||
Recruiting |
NCT06040528 -
Early Discharge Pathway Registry
|
||
Recruiting |
NCT02900001 -
Routinely Deferred Versus Early Intervention in Elderly Patients With Non-ST-elevation Myocardial Infarction
|
N/A | |
Completed |
NCT01491074 -
Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction
|
Phase 2 | |
Recruiting |
NCT01555177 -
Study of Coronary Plaque Rupture in Heart Attack Following Surgery Using Optical Coherence Tomography (OCT)
|
N/A | |
Not yet recruiting |
NCT05587621 -
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
|
N/A | |
Completed |
NCT03391908 -
Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
|